Masimo Corporation
NASDAQ•MASI
CEO: Ms. Michelle M. Brennan
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 2007-08-08
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.
Contact Information
Market Cap
$9.42B
P/E (TTM)
-62.1
57.7
Dividend Yield
--
52W High
$175.90
52W Low
$125.94
52W Range
Rank35Top 29.9%
4.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$412.50M+0.00%
4-Quarter Trend
EPS
$1.25+0.00%
4-Quarter Trend
FCF
$53.40M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Revenue Grew 9.4% Total revenue reached $1,526.9 M, driven by higher consumable sales and an extra selling week.
Gross Margin Expanded Gross profit margin improved to 61.9% from 56.9%, aided by strategic realignment benefits.
Danaher Merger Agreement Definitive agreement signed to be acquired by Danaher for $180.00 cash per share, expected H2 2026 close.
R&D Spending Reduced Research and development expenses decreased 30.6% to $126.4 M following strategic realignment initiatives.
Risk Factors
Merger Completion Uncertainty Merger closing depends on regulatory approvals; failure to obtain them could adversely affect financial results.
Willow Cross-Licensing Dispute Ongoing arbitration with Willow over licensing agreement may result in damages or limit rainbow technology growth.
Customer Purchase Concentration Loss of single large distributor, representing 18.8% of revenue, could significantly reduce net sales.
Cybersecurity Incident Impact Unauthorized network activity in April 2025 temporarily impacted manufacturing and order fulfillment capabilities.
Outlook
Focus on Merger Closing Management prioritizing customary closing conditions to finalize the Danaher acquisition in the second half of 2026.
Expand Growth Markets Strategy focuses on expanding patient monitoring into outpatient and ambulatory surgery centers using existing technologies.
Manage Regulatory Evolution Must adapt internal controls and practices to evolving global data privacy laws, increasing compliance costs.
Intellectual Property Defense Will continue litigation against Apple and defend patents; success in these efforts is not guaranteed.
Peer Comparison
Revenue (TTM)
$45.43B
$13.18B
$11.24B
Gross Margin (Latest Quarter)
97.9%
91.6%
72.0%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| GMED | $11.60B | 21.5 | 12.4% | 2.2% |
| GH | $11.44B | -26.9 | 164.9% | 83.6% |
| JAZZ | $11.21B | -31.2 | -8.8% | 46.4% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.5%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:May 5, 2026
EPS:$1.43
|Revenue:$398.10M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data